Status:
RECRUITING
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
Eligibility Criteria
Inclusion
- Participant aged 18 years or older
- Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10%
- Participant newly initiated deucravacitinib according to the label
- Provided written informed consent to participate in the study
Exclusion
- Participating in or planning to participate in an interventional clinical trial
- Concomitant use of other systemic treatments for psoriasis at baseline
- Prior treatment of deucravacitinib
Key Trial Info
Start Date :
January 20 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06512337
Start Date
January 20 2025
End Date
August 31 2026
Last Update
February 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510091